- List
- By Topic
- On Map
- Search Details

"Ewings sarcoma"
Need help? See RSS Feeds
Choose a feed type:

"Ewings sarcoma" (243 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03359005 | Recruiting | Irinotecan and Temozolomide for Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
22 | All | Child, Adult, Senior | NCT03359005 | PKUPH-EWS-01 | February 7, 2018 | February 28, 2020 | February 28, 2025 | December 2, 2017 | April 5, 2018 |
|
||
2 | NCT01969942 | Withdrawn | A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma |
|
|
Interventional | Phase 1 |
|
Other |
|
|
0 | All | up to 30 Years (Child, Adult) | NCT01969942 | 13.0176 | ASCT | April 2013 | October 2016 | October 2016 | October 25, 2013 | May 9, 2017 |
|
|
3 | NCT02063022 | Recruiting | Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma |
|
|
Interventional | Phase 3 |
|
Other |
|
|
220 | All | up to 40 Years (Child, Adult) | NCT02063022 | ISG/AIEOP EW-1 | EW-1 | February 2009 | December 2018 | December 2018 | February 14, 2014 | April 11, 2018 |
|
|
4 | NCT02511132 | Active, not recruiting | A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
22 | All | 2 Years and older (Child, Adult, Senior) | NCT02511132 | CL-PTL-121 | May 25, 2017 | June 2018 | December 2018 | July 29, 2015 | January 23, 2018 |
|
||
5 | NCT03029481 | Available | Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma |
|
|
Expanded Access |
|
Other / Industry | All | 48 Years to 50 Years (Adult) | NCT03029481 | 17-000019 JCCCID738 |
January 24, 2017 | February 22, 2018 | ||||||||||
6 | NCT01696669 | Unknown † | Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults |
|
|
Interventional | Phase 2 |
|
Other |
|
|
43 | All | up to 40 Years (Child, Adult) | NCT01696669 | GEIS-21 2009-016027-62 |
April 2010 | December 2016 | December 2016 | October 1, 2012 | August 18, 2015 |
|
||
7 | NCT02736565 | Active, not recruiting | Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
4 | All | 8 Years and older (Child, Adult, Senior) | NCT02736565 | CL-PTL-001 | October 2016 | September 2018 | December 2019 | April 13, 2016 | February 22, 2018 |
|
||
8 | NCT01858168 | Recruiting | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma |
|
|
Interventional | Phase 1 |
|
Other |
|
|
93 | All | 16 Years and older (Child, Adult, Senior) | NCT01858168 | 13-115 | July 2013 | July 2018 | July 2019 | May 21, 2013 | November 13, 2017 |
|
||
9 | NCT00987636 | Recruiting | Study in Localized and Disseminated Ewing Sarcoma |
|
|
Interventional | Phase 3 |
|
Other |
|
|
1163 | All | 48 Months to 50 Years (Child, Adult) | NCT00987636 | 108128 2008-003658-13 |
EWING2008 | October 2009 | March 2019 | March 2019 | October 1, 2009 | May 20, 2016 |
|
|
10 | NCT01734863 | Withdrawn | Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients |
|
|
Interventional | Phase 3 |
|
Other |
|
|
0 | All | 1 Year to 18 Years (Child, Adult) | NCT01734863 | CCHE-BoneT002 | September 2012 | September 2022 | December 2022 | November 28, 2012 | January 12, 2016 |
|
||
11 | NCT02546544 | Completed | Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
40 | All | 18 Years to 70 Years (Adult, Senior) | NCT02546544 | OCTO_038 2012-000616-28 |
LINES | March 2014 | July 15, 2016 | July 15, 2016 | September 11, 2015 | March 22, 2017 |
|
|
12 | NCT02044120 | Recruiting | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma |
|
|
Interventional | Phase 1 |
|
Other |
|
|
50 | All | 13 Years and older (Child, Adult, Senior) | NCT02044120 | ESP1/SARC025 | May 2014 | September 2018 | February 2019 | January 23, 2014 | April 11, 2018 |
|
||
13 | NCT01583543 | Completed Has Results |
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
12 | All | 18 Years and older (Adult, Senior) | NCT01583543 | 11-470 | May 2012 | January 2014 | November 2014 | April 24, 2012 | May 19, 2017 | May 19, 2017 |
|
|
14 | NCT00568464 | Terminated | Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) |
|
|
Interventional | Phase 2 |
|
Other |
|
|
10 | All | 10 Years to 65 Years (Child, Adult) | NCT00568464 | VCD/IE-ESFT | March 2007 | May 2009 | September 2009 | December 6, 2007 | July 7, 2009 |
|
||
15 | NCT02727387 | Recruiting | Protocol for the Treatment of Metastatic Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
70 | All | up to 40 Years (Child, Adult) | NCT02727387 | ISG/AIEOP EW-2 | EW-2 | May 2009 | May 2018 | May 2020 | April 4, 2016 | April 11, 2018 |
|
|
16 | NCT00492141 | Completed | Aerosol L9-NC and Temozolomide in Ewing's Sarcoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
10 | All | 10 Years and older (Child, Adult, Senior) | NCT00492141 | 2005-0889 | June 2006 | May 2007 | September 2009 | June 27, 2007 | August 2, 2012 |
|
||
17 | NCT00339898 | Completed | Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma |
|
Observational |
|
NIH | 414 | All | 2 Years to 30 Years (Child, Adult) | NCT00339898 | 999904135 04-C-N135 |
March 12, 2004 | January 13, 2015 | June 21, 2006 | April 17, 2018 |
|
|||||||
18 | NCT01864109 | Recruiting | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
83 | All | 1 Year to 40 Years (Child, Adult) | NCT01864109 | 13-068 | May 2013 | May 2019 | May 2019 | May 29, 2013 | August 3, 2017 |
|
||
19 | NCT00038142 | Terminated | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients |
|
|
Interventional | Phase 2 |
|
Other |
|
|
46 | All | 3 Years to 60 Years (Child, Adult) | NCT00038142 | ID97-198 NCI-2012-01285 |
November 1997 | March 2016 | March 2016 | May 30, 2002 | March 4, 2016 |
|
||
20 | NCT00560235 | Completed Has Results |
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
138 | All | 10 Years and older (Child, Adult, Senior) | NCT00560235 | A4021020 | March 2008 | March 2010 | October 2012 | November 19, 2007 | October 28, 2015 | February 28, 2014 |
|
|
21 | NCT03416517 | Recruiting | Anlotinib and Irinotecan for Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
22 | All | 3 Years to 18 Years (Child, Adult) | NCT03416517 | PKUPH-EWS-02 | January 22, 2018 | February 2020 | December 2020 | January 31, 2018 | April 12, 2018 |
|
||
22 | NCT03011528 | Recruiting | First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years |
|
|
Interventional | Phase 2 |
|
Other |
|
|
45 | All | 2 Years to 50 Years (Child, Adult) | NCT03011528 | IC 2015-13 CombinaiR3 | CombinaiR3 | December 2016 | May 2020 | December 2022 | January 5, 2017 | December 18, 2017 |
|
|
23 | NCT01876303 | Completed | Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma |
|
|
Observational |
|
Other / NIH |
|
|
1650 | All | Child, Adult, Senior | NCT01876303 | AEPI10N5 NCI-2012-02210 U10CA098543 |
December 2012 | July 2016 | June 12, 2013 | July 14, 2016 |
|
||||
24 | NCT01610570 | Terminated Has Results |
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma |
|
|
Interventional | Phase 1 Phase 2 |
|
NIH |
|
|
8 | All | 1 Year and older (Child, Adult, Senior) | NCT01610570 | 120135 12-C-0135 |
May 10, 2012 | May 21, 2014 | May 21, 2014 | June 4, 2012 | March 2, 2018 | February 15, 2016 |
|
|
25 | NCT02657005 | Recruiting | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
45 | All | 10 Years and older (Child, Adult, Senior) | NCT02657005 | TK216-01 | May 2016 | September 2018 | December 2018 | January 15, 2016 | April 17, 2018 |
|
||
26 | NCT01780779 | Unknown † | Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults |
|
|
Observational |
|
Other |
|
|
25 | All | 6 Years to 30 Years (Child, Adult) | NCT01780779 | FUBEO S51516 |
FUBEO | June 2009 | June 2013 | June 2014 | January 31, 2013 | January 31, 2013 |
|
||
27 | NCT02472392 | Completed | Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma |
|
|
Interventional | Phase 1 |
|
Other |
|
|
10 | All | up to 30 Years (Child, Adult) | NCT02472392 | 13.0167 | Ewing/Allo | April 2013 | December 2016 | December 2016 | June 15, 2015 | May 9, 2017 |
|
|
28 | NCT00898053 | Completed | Study of Tumor Samples From Patients With Ewing Sarcoma |
|
|
Observational |
|
Other / NIH |
|
|
200 | All | up to 50 Years (Child, Adult) | NCT00898053 | AEWS08B1 NCI-2009-00372 U10CA098543 |
September 2008 | May 2016 | May 2016 | May 12, 2009 | May 17, 2016 |
|
|||
29 | NCT00618813 | Completed Has Results |
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
35 | All | up to 30 Years (Child, Adult) | NCT00618813 | AEWS07P1 NCI-2009-00371 CDR0000586282 U10CA098543 COG-AEWS07P1 |
March 2008 | March 2010 | February 20, 2008 | September 25, 2014 | February 10, 2014 |
|
||
30 | NCT00824083 | Completed | Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment |
|
Observational |
|
Other |
|
|
950 | All | 6 Years to 60 Years (Child, Adult) | NCT00824083 | 01ER0807 | July 2009 | July 2015 | July 2015 | January 16, 2009 | April 28, 2016 |
|
||||
31 | NCT01313884 | Terminated Has Results |
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
3 | All | 13 Years and older (Child, Adult, Senior) | NCT01313884 | IRB-20323 SU-03082011-7559 SARCOMA0007 |
May 2011 | July 2014 | July 2014 | March 14, 2011 | November 24, 2017 | February 2, 2017 |
|
|
32 | NCT00541411 | Unknown † | Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma |
|
|
Interventional | Not Applicable |
|
Other |
|
|
10 | All | Child, Adult, Senior | NCT00541411 | RAC#2031-065 | June 2003 | June 2013 | June 2013 | October 10, 2007 | April 17, 2012 | |||
33 | NCT03495921 | Not yet recruiting New |
Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
140 | All | 2 Years and older (Child, Adult, Senior) | NCT03495921 | CL-PTL-130 | June 15, 2018 | December 31, 2021 | July 1, 2022 | April 12, 2018 | April 12, 2018 | |||
34 | NCT01882231 | Terminated | Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
6 | All | 13 Years and older (Child, Adult, Senior) | NCT01882231 | VICC SAR 1275 U01CA142565 |
March 2013 | April 25, 2016 | April 25, 2016 | June 20, 2013 | May 8, 2017 |
|
||
35 | NCT03441360 | Recruiting | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
30 | All | 12 Months to 18 Years (Child, Adult) | NCT03441360 | E7389-G000-223 | January 23, 2018 | June 2020 | January 2021 | February 21, 2018 | March 15, 2018 |
|
||
36 | NCT00048984 | Completed | Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma |
|
|
Observational |
|
Other / NIH |
|
|
637 | All | up to 50 Years (Child, Adult) | NCT00048984 | AEWS02B1 NCI-2012-02494 CDR0000257115 COG-AEWS02B1 NCI-03-C-0216 U10CA098543 |
January 2003 | February 2013 | January 27, 2003 | June 24, 2013 |
|
||||
37 | NCT01585649 | Completed | PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
21 | All | 2 Years to 17 Years (Child) | NCT01585649 | XM22-07 2011-004742-18 |
July 2012 | June 2014 | April 2015 | April 26, 2012 | May 18, 2016 |
|
||
38 | NCT00001335 | Completed | New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
90 | All | Child, Adult, Senior | NCT00001335 | 930125 93-C-0125 |
April 1993 | January 2002 | November 4, 1999 | March 4, 2008 |
|
||||
39 | NCT00899990 | Active, not recruiting | Collecting and Storing Biological Samples From Patients With Ewing Sarcoma |
|
|
Observational |
|
Other / NIH |
|
|
900 | All | up to 21 Years (Child, Adult) | NCT00899990 | AEWS07B1 NCI-2009-00370 COG-AEWS07B1 U10CA098543 |
February 2008 | January 2100 | January 2100 | May 12, 2009 | December 13, 2017 |
|
|||
40 | NCT00516295 | Completed Has Results |
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
7 | All | 1 Year to 29 Years (Child, Adult) | NCT00516295 | NCI-2009-00369 AEWS0521 U10CA098543 |
February 2008 | August 2009 | January 2010 | August 15, 2007 | September 2, 2014 | September 2, 2014 |
|
|
41 | NCT01946529 | Active, not recruiting Has Results |
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
24 | All | up to 25 Years (Child, Adult) | NCT01946529 | ESFT13 NCI-2013-01657 |
December 27, 2013 | August 2015 | July 2026 | September 19, 2013 | October 19, 2017 | October 19, 2016 |
|
|
42 | NCT01365949 | Completed | Biomarker in Tissue Samples From Patients With Ewing Sarcoma |
|
|
Observational |
|
Other / NIH |
|
|
40 | All | up to 120 Years (Child, Adult, Senior) | NCT01365949 | AEWS11B1 COG-AEWS11B1 NCI-2011-02857 |
May 2011 | July 2016 | June 3, 2011 | July 11, 2016 | |||||
43 | NCT01480518 | Completed | Biomarkers in Tissue Samples From Patients With Ewing Sarcoma |
|
|
Observational |
|
Other / NIH |
|
|
166 | All | up to 50 Years (Child, Adult) | NCT01480518 | AEWS11B2 COG-AEWS11B2 NCI-2012-00083 |
December 2011 | January 2012 | January 2012 | November 29, 2011 | May 12, 2015 | ||||
44 | NCT01210209 | Unknown † | Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives |
|
|
Observational |
|
Other |
|
600 | All | Child, Adult, Senior | NCT01210209 | CDR0000683940 CLCC-IC-2009-02 2009-A00558-49 EU-21064 |
September 2009 | September 2011 | September 28, 2010 | August 26, 2013 |
|
|||||
45 | NCT00276692 | Completed | Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
35 | All | up to 19 Years (Child, Adult) | NCT00276692 | CCLG-ET-2003-04 CDR0000454550 EU-20582 |
August 2003 | September 2008 | July 2009 | January 13, 2006 | June 26, 2013 |
|
||
46 | NCT00470275 | Completed Has Results |
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
10 | All | up to 30 Years (Child, Adult) | NCT00470275 | AEWS0621 CDR0000542650 COG-AEWS0621 |
May 2007 | August 2008 | December 2013 | May 7, 2007 | October 20, 2014 | November 1, 2013 |
|
|
47 | NCT02243605 | Recruiting | Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
90 | All | 12 Years and older (Child, Adult, Senior) | NCT02243605 | NCI-2014-01927 CABONE 9620 |
December 19, 2014 | June 30, 2019 | September 18, 2014 | March 5, 2018 |
|
|||
48 | NCT00002516 | Unknown † | Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma |
|
|
Interventional | Phase 3 |
|
Other |
|
All | up to 35 Years (Child, Adult) | NCT00002516 | CDR0000078196 GER-GPOH-EICESS-92 MRC-EICESS-92 EU-92030 EU-205116 UKCCSG-ET1993-02 |
July 1992 | May 5, 2004 | September 17, 2013 |
|
||||||
49 | NCT00334867 | Withdrawn | Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma |
|
|
Interventional | Phase 3 |
|
Other / NIH |
|
|
0 | All | up to 50 Years (Child, Adult) | NCT00334867 | AEWS0531 COG-AEWS0531 CDR0000483611 |
December 2005 | January 2006 | June 8, 2006 | June 28, 2013 | ||||
50 | NCT00743496 | Completed | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma |
|
|
Interventional | Phase 1 |
|
Other |
|
|
50 | All | up to 21 Years (Child, Adult) | NCT00743496 | SJGD2 ED FDN NCI-2011-01150 |
October 8, 2008 | April 1, 2014 | April 18, 2014 | August 28, 2008 | August 17, 2017 |
|
† Study has passed its completion date and status has not been verified in more than two years.